Research Article

The Correlation of PPARα Activity and Cardiomyocyte Metabolism and Structure in Idiopathic Dilated Cardiomyopathy during Heart Failure Progression

Table 1

Clinical data.

Control
()
LVEF > 60%
Group (I)
()
LVEF 50–45%
Group (II)
()
LVEF 44–30%
Group (III)
()
LVEF < 30%

Age (y)32.6 ± 10.834 ± 9.3938.8 ± 7.8741.13 ± 11.83
Men/women ()5/18/212/311/4
NYHA class1.22 ± 0.441.6 ± 0.572.10 ± 0.47
BMI22.05 ± 0.9221.7 ± 1.4326.58 ± 2.8925.35 ± 3.88
LV EF [%]63 ± 447.77 ± 2.8135.80 ± 3.4222.33 ± 4.06
LV EDD [mm]51.34 ± 3.7453.44 ± 1.7465.13 ± 7.3871.53 ± 6.65
LV ESD [mm]30 ± 1.434.55 ± 4.7447.73 ± 8.7560.13 ± 5.46
ESV [mL]45 ± 852 ± 4.2124.2 ± 44.76188.93 ± 49.25
EDV [mL]102 ± 13.2105 ± 24.8182.86 ± 57.9241.8 ± 79.15
NT-proBNP [pg/mL]64.4 ± 1.478.61 ± 1.3999.8 ± 1625.11709.6 ± 2314.3
Creatinine [µmol/L]68.9 ± 10.272.01 ± 10.572.22 ± 13.0976.46 ± 12.5
Glucose [mmol/L]5 ± 0.405.03 ± 0.455.02 ± 0.405.51 ± 0.91
Cholesterol [mmol/L]3.3 ± 1.423.33 ± 1.975.13 ± 0.584.99 ± 1.55
TG [mmol/L]1.45 ± 0.210.85 ± 0.741.62 ± 0.771.53 ± 0.86
HDL [mmol/L]1.2 ± 0.811.05 ± 0.841.39 ± 3.141.40 ± 0.56
LDL [mmol/L]2.12 ± 0.502.01 ± 1.393.14 ± 0.602.45 ± 1.34
Diuretics1814
Digitalis149
ACE inhibitors233
β-blockers365